Loading…
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $96M | $-12M | $-5M | $0M | -1.2% | 28.9% | -77.2% |
| 2024 | $75M | $4M | $-20M | $5M | -5.8% | 9.7% | -70.3% |
| 2023 | $68M | $-7M | $-68M | $-19M | -20.1% | -10.8% | -51.4% |
| 2022 | $76M | $6M | $-140M | $-19M | -38.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 76.24 | 68.02 | 74.65 | 96.21 |
| Operating Revenue | - | 76.24 | 68.02 | 74.65 | 96.21 |
| Cost Of Revenue | - | 29.33 | 26.70 | 24.55 | 34.10 |
| Gross Profit | - | 46.91 | 41.32 | 50.10 | 62.12 |
| Operating Expense | - | 57.59 | 60.72 | 54.57 | 78.72 |
| Research And Development | - | 8.67 | 5.52 | 4.75 | 23.09 |
| Selling General And Administration | - | 44.93 | 54.17 | 49.56 | 55.37 |
| Total Expenses | - | 86.92 | 87.41 | 79.12 | 112.82 |
| Operating Income | - | -10.68 | -19.40 | -4.48 | -16.60 |
| Total Operating Income As Reported | - | -5.92 | -17.20 | -4.48 | -16.60 |
| EBITDA | - | 5.80 | -7.10 | 4.18 | -11.92 |
| Normalized EBITDA | - | 0.34 | -14.41 | 8.26 | -11.92 |
| EBIT | - | -10.68 | -19.40 | -4.48 | -16.60 |
| Net Interest Income | - | -0.28 | -1.41 | -0.77 | 2.71 |
| Other Non Operating Income Expenses | - | 0.66 | 1.27 | 0.49 | 1.82 |
| Other Income Expense | - | 6.11 | 8.58 | -3.58 | 1.82 |
| Net Non Operating Interest Income Expense | - | -0.28 | -1.41 | -0.77 | 2.71 |
| Pretax Income | - | -4.85 | -12.22 | -8.82 | -12.08 |
| Tax Provision | - | -5.24 | -0.06 | -0.04 | 0.05 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0.22 | 0.07 | -0.02 | 0 |
| Net Income Continuous Operations | - | 0.39 | -12.16 | -8.78 | -12.13 |
| Net Income From Continuing And Discontinued Operation | - | -139.80 | -68 | -20.18 | -4.60 |
| Net Income From Continuing Operation Net Minority Interest | - | 0.39 | -12.16 | -8.78 | -12.13 |
| Net Income | - | -139.80 | -68 | -20.18 | -4.60 |
| Net Income Common Stockholders | - | -139.80 | -68 | -20.18 | -4.60 |
| Net Income Including Noncontrolling Interests | - | -139.80 | -68 | -20.18 | -4.60 |
| Normalized Income | - | -4.84 | -19.39 | -4.73 | -12.13 |
| Diluted NI Availto Com Stockholders | - | -139.80 | -68 | -20.18 | -4.60 |
| Basic Average Shares | - | 42.48 | 43.72 | 46.07 | 47.75 |
| Diluted Average Shares | - | 42.48 | 43.72 | 46.07 | 48.65 |
| Reconciled Depreciation | - | 16.47 | 12.30 | 8.66 | 4.69 |
| Reconciled Cost Of Revenue | - | 16.85 | 15.44 | 16.15 | 29.67 |
| Total Unusual Items | - | 5.45 | 7.31 | -4.07 | 0 |
| Total Unusual Items Excluding Goodwill | - | 5.45 | 7.31 | -4.07 | 0 |
| Net Income Discontinuous Operations | - | -140.19 | -55.84 | -11.40 | 7.54 |
| Special Income Charges | - | 4.75 | 7.31 | 0 | 0 |
| Impairment Of Capital Assets | 0 | 110.36 | 15.48 | - | - |
| Restructuring And Mergern Acquisition | - | -4.75 | -7.31 | 0 | 0 |
| Gain On Sale Of Security | -0.12 | 0.70 | - | -4.07 | - |
| Depreciation Amortization Depletion Income Statement | - | 3.99 | 1.03 | 0.26 | 0.26 |
| Depreciation And Amortization In Income Statement | - | 3.99 | 1.03 | 0.26 | 0.26 |
| General And Administrative Expense | - | 33.26 | 42.79 | 40.63 | 45.52 |
| Other Gand A | - | 33.26 | 42.79 | 40.63 | 45.52 |
| Total Other Finance Cost | - | 0.28 | 1.41 | 0.77 | -2.71 |
| Selling And Marketing Expense | - | 11.67 | 11.38 | 8.93 | 9.85 |
| Otherunder Preferred Stock Dividend | 0 | 0 | - | - | - |
| Earnings From Equity Interest | 0 | - | - | - | - |
| Average Dilution Earnings | 0 | 0 | - | - | - |
| Amortization | - | 3.99 | 1.03 | 0.26 | 0.26 |
| Amortization Of Intangibles Income Statement | - | 3.99 | 1.03 | 0.26 | 0.26 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| BioLife Solutions, Inc.this co. | BLFS | $1.3B | -288.04 | 3.56 | -1.2% | -109.81 |
| UroGen Pharma Ltd. | URGN | $1.3B | -8.76 | -12.75 | 145.5% | -10.04 |
| Bicara Therapeutics Inc. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B |
| - |
| - |
| - |
| - |
| - |
| - |
| -21.66 |
| 7.99 |
| -36.9% |
| -50.52 |
| Tandem Diabetes Care, Inc. | TNDM | $1.3B | -6.51 | 8.59 | -131.9% | -9.55 |
| AdaptHealth Corp. | AHCO | $1.3B | -18.70 | 0.87 | -4.7% | 6.60 |
| Teladoc Health, Inc. | TDOC | $1.3B | -6.59 | 0.95 | -14.5% | 9.83 |
| Enovis Corporation | ENOV | $1.3B | -1.11 | 0.88 | -79.5% | -3.20 |
| Peer Median | - | -9.16 | 2.15 | -35.6% | -8.78 | |